Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company
focused on developing and commercializing innovative,
interventional technologies intended to transform care and improve
patients’ lives, announced today that data from studies of two of
its proprietary glaucoma and dry eye technologies, the OMNI
Surgical System (“OMNI”) and the TearCare System (“TearCare”), will
be presented in two oral presentations and two posters at this
year’s ASCRS Annual meeting April 5th to 8th in Boston, MA.
OMNI technology facilitates surgeons’ ability to
perform a comprehensive, implant-free, minimally invasive glaucoma
surgical procedure in adults with primary open-angle glaucoma
(“POAG”). TearCare technology enables a proprietary, interventional
eyelid procedure for diseased meibomian glands and is intended for
the application of localized heat therapy in adult patients with
evaporative dry eye disease (“DED”) due to meibomian gland
dysfunction, when used in conjunction with manual expression of the
meibomian glands.
“We are excited that additional data supporting
the efficacy and safety of our OMNI and TearCare technologies will
be presented at ASCRS, the largest annual gathering for anterior
segment surgeons,” said Paul Badawi, CEO and co-founder of Sight
Sciences. “In addition to our existing robust body of clinical
evidence, we now have additional data showing impressive OMNI
results at 36-months, which demonstrate the vital long-term element
of OMNI’s efficacy. We are also pleased that new TearCare data will
be shared that supports the use of TearCare technology as a primary
treatment for DED.”
Oral Presentation: OMNI Surgical
System
- 36-Month Outcomes for Canaloplasty and Trabeculotomy Combined
with Cataract Surgery: Extended Follow-up from the Gemini Study –
oral presentation on Sunday, April 7th at 3:50 PM ET at the BCEC
Meeting level 2 room 259A. Lead author: Arkadiy Yadgarov, MD
“Long-term data is key in the selection of a
surgical treatment,” said Arkadiy Yadgarov, MD, of Omni Eye
Services of Atlanta, GA. “The 12-month GEMINI trial demonstrated
efficacy of the OMNI procedure combined with cataract surgery for
IOP and medication reduction in mild-to-moderate glaucoma.1,2 This
extension of the trial shows that these positive 12-month outcomes
were sustained through 36 months.”
Oral and Paper Presentations: TearCare
System
- Tear Break-up, Meibomian Gland, and Dry Eye Symptom Improvement
for Cyclosporine-Treated Patients after Localized Heat Therapy
Treatment (SAHARA Cross-Over/phase 2) – oral presentation on
Sunday, April 7 at 3:30 PM ET at the BCEC Meeting level 2, room
259B. Lead author: Brandon Ayres, MD
- Rapid Improvement in the Signs and Symptoms of Dry Eye Disease
with Localized Heat Therapy (LHT) or Cyclosporine Ophthalmic
Emulsion (CsA) (SAHARA subanalysis) – poster presentation.
Lead author: Julio Echegoyen, MD, PhD
- Localized Heat Therapy (LHT) Compared to Cyclosporine
Ophthalmic Emulsion (CsA): A Subanalysis on Age, Gender, and
Disease Burden (SAHARA subanalysis) – poster presentation.
Lead author: Jennifer Loh, MD
“These data once again support the conclusion
that TearCare should be a preferred treatment for DED associated
with meibomian gland dysfunction,” says Brandon Ayres, MD, of Wills
Eye Hospital, Philadelphia, PA. “In phase 1 of the SAHARA trial, we
found the interventional TearCare procedure provided statistically
superior and sustained improvement in tear break-up time and
multiple measures of meibomian gland secretion when compared to
treatment with Restasis.3 In
phase 2 (cross-over) of the study, we found that a single TearCare
procedure improved signs and symptoms for patients beyond what was
achieved with six months of Restasis.”
Red Carpet EventAdditionally,
at ASCRS, Sight Sciences will be hosting a red carpet event at its
booth (#545), where the company will celebrate its shared
commitment to elevating eyecare for the benefit of patients. The
event will be on Saturday, April 6, 2024, from 3:45 PM to 4:30 PM
ET. Learn more about this and other Sight Sciences activities at
ASCRS at www.sightsciences.com/ascrs
About Sight SciencesSight
Sciences is an eyecare technology company focused on developing and
commercializing innovative and interventional solutions intended to
transform care and improve patients’ lives. Using minimally
invasive or non-invasive approaches to target the underlying causes
of the world’s most prevalent eye diseases, Sight Sciences seeks to
create more effective treatment paradigms that enhance patient care
and supplant conventional outdated approaches. The Company’s OMNI®
Surgical System is an implant-free glaucoma surgery technology (i)
indicated in the United States to reduce intraocular pressure in
adult patients with primary open-angle glaucoma; and (ii) CE Marked
for the catheterization and transluminal viscodilation of Schlemm’s
canal and cutting of the trabecular meshwork to reduce intraocular
pressure in adult patients with open-angle glaucoma. Glaucoma is
the world’s leading cause of irreversible blindness. The SION®
Surgical Instrument is a bladeless, manually operated device used
in ophthalmic surgical procedures to excise trabecular meshwork.
The Company’s TearCare® System is 510(k) cleared in the United
States for the application of localized heat therapy in adult
patients with evaporative dry eye disease due to meibomian gland
dysfunction (“MGD”), enabling clearance of gland obstructions by
physicians to address the leading cause of dry eye disease. The
Company’s SION® Surgical Instrument is a manually operated device
used in ophthalmic surgical procedures to excise trabecular
meshwork. Visit sightsciences.com for more information.
Sight Sciences and TearCare are trademarks of
Sight Sciences registered in the United States. OMNI and SION are
trademarks of Sight Sciences registered in the United States,
European Union and other territories. Restasis is a registered
trademark of Allergan, an AbbVie company.
All educational content of the ASCRS Annual
Meeting is planned by its program committee, and ASCRS does not
endorse, promote, approve, or recommend the use of any products,
devices, or services.
© 2024 Sight Sciences. All rights reserved.
04/2024 SS-3165-US.v1
Forward-Looking StatementsThis
press release, together with other statements and information
publicly disseminated by the Company, contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The Company intends
such forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995 and includes this
statement for purposes of complying with these safe harbor
provisions. Any statements made in this press release that are not
statements of historical fact, including statements about our
beliefs and expectations, are forward-looking statements and should
be evaluated as such. Forward-looking statements include timing for
presentation of OMNI and TearCare-related clinical trial results
and use of TearCare as a preferred treatment for DED associated
with meibomian gland dysfunction. These statements often include
words such as “anticipate,” “expect,” “suggests,” “plan,”
“believe,” “intend,” “estimates,” “targets,” “projects,” “should,”
“could,” “would,” “may,” “will,” “forecast” and other similar
expressions. We base these forward-looking statements on our
current expectations, plans and assumptions that we have made in
light of our experience in the industry, as well as our perceptions
of historical trends, current conditions, expected future
developments and other factors we believe are appropriate under the
circumstances at such time. Although we believe that these
forward-looking statements are based on reasonable assumptions at
the time they are made, you should be aware that many factors could
affect our business, results of operations and financial condition
and could cause actual results to differ materially from those
expressed in the forward-looking statements. These forward-looking
statements are subject to and involve numerous risks, uncertainties
and assumptions, including those discussed under the caption “Risk
Factors” in our filings with the U.S. Securities and Exchange
Commission, as may be updated from time to time in subsequent
filings, and you should not place undue reliance on these
statements. These cautionary statements are made only as of the
date of this press release. We undertake no obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
Media Contact pr@sightsciences.com
Investor ContactPhilip TaylorGilmartin
Group415.937.5406investor.relations@sightsciences.com
1. Gallardo MJ, Pyfer MF, Vold SD, et al. Canaloplasty and
Trabeculotomy Combined with Phacoemulsification for Glaucoma:
12-Month Results of the GEMINI Study. Clin Ophthalmol.
2022;16:1225-1234. Published 2022 Apr 21.
doi:10.2147/OPTH.S362932
2. Greenwood MD, Yadgarov A, Flowers BE, et al. 36-Month
Outcomes from the Prospective GEMINI Study: Canaloplasty and
Trabeculotomy Combined with Cataract Surgery for Patients with
Primary Open-Angle Glaucoma. Clin Ophthalmol. 2023;17:3817-3824.
Published 2023 Dec 12. doi:10.2147/OPTH.S446486
3. Ayres BD, Bloomenstein MR, Loh J, et al. A Randomized,
Controlled Trial Comparing Tearcare® and Cyclosporine Ophthalmic
Emulsion for the Treatment of Dry Eye Disease (SAHARA). Clin
Ophthalmol. 2023;17:3925-3940. Published 2023 Dec 18.
doi:10.2147/OPTH.S442971
Sight Sciences (NASDAQ:SGHT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sight Sciences (NASDAQ:SGHT)
Historical Stock Chart
From Oct 2023 to Oct 2024